logo
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos

ImmunoHub.org – Immuno-Oncology Essentials – Home › Forums › Immunotherapy

  • This category has 30 topics, 84 replies, and was last updated March 1, 2018 at 12:16 am by Lisa Kottschade.
    • Forum
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 6
    • 13
    • Adjuvant Immunotherapy in stage IIIA patients

      March 1, 2018 at 12:16 am

      Lisa Kottschade

    • Dosing and administration
    • 2
    • 14
    • Reply To: Infusion times

      February 15, 2018 at 3:41 pm

      Lisa Kottschade

    • Side-effect management
    • 12
    • 47
    • Reply To: ASCO/NCCN guidlines now out

      February 23, 2018 at 5:53 pm

      Mollie Reed

    • Reimbursement
    • 2
    • 12
    • Reply To: Reimbursement for infliximab

      February 17, 2018 at 11:10 pm

      Krista Rubin

    • Other
    • 8
    • 28
    • Reply To: Influenza and Tamiflu and Immunotherapy

      February 25, 2018 at 10:12 pm

      Kathleen Madden

  •  

Login

Log In
Register Lost Password

Latest Activity

  • New BRAF/MEK inhibitors coming to market
    topic by Lisa Kottschade
    March 1
    in Dosing and administration
  • Adjuvant Immunotherapy in stage IIIA patients
    topic by Lisa Kottschade
    March 1
    in Expectations for therapy
  • Influenza and Tamiflu and Immunotherapy
    reply by Kathleen Madden
    February 25
    in Other
  • ASCO/NCCN guidlines now out
    reply by Mollie Reed
    February 23
    in Side-effect management
  • hepatotoxicity
    reply by Mollie Reed
    February 23
    in Side-effect management
© 2023 ImmunoHub.org. All rights reserved.
  • About
  • Terms
  • Privacy
  • Contact